Transglutaminase 2 Inhibitor for Celiac Disease In a phas | UPDATES IN MEDICINE
Transglutaminase 2 Inhibitor for Celiac Disease
In a phase 2 proof-of-concept trial, patients with celiac disease controlled on a gluten-free diet were assigned to one of three dose levels of ZED1227 (a selective transglutaminase 2 inhibitor) or placebo. Patients were challenged with 3 g of gluten daily for 6 weeks. Comparison of duodenal-biopsy samples between baseline and 6 weeks showed that ZED1227 attenuated gluten-induced mucosal damage. #gastroenterology
